{'fraction_non_alphanumeric': 0.0223463687150838, 'fraction_numerical': 0.017690875232774673, 'mean_word_length': 5.554878048780488, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Population based studies of biological antirheumatic drug use in southern Sweden: comparison with pharmaceutical sales

This study aimed at assessing the drug costs for biological treatments in a geographically defined area in southern Sweden (Scania province, population 1 145 090, November 2002), and at identifying any geographical differences and changes with time in the overall use of these compounds. Also, we wanted to investigate the completeness of the registry held by the South Swedish Arthritis Treatment Group (SSATG).1 During the study period no economic prescribing restrictions existed for these drugs in the region. The Swedish social security system covers all prescribed drug costs exceeding SEK 1800 (€170) a year to all patients in need, where need is based on their physician’s judgment. Thus, the use of biological antirheumatic treatment was limited only by restricted drug availability and capacity of the administration facilities. Medical practice was, however, under strong influence by guidelines from the Swedish Rheumatological Association. …